

Hisashi Tsurumi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6827639/publications.pdf>

Version: 2024-02-01

85
papers

1,874
citations

218381
26
h-index

288905
40
g-index

88
all docs

88
docs citations

88
times ranked

2617
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, 9.	2.0	2
2	Unrelated bone marrow transplantation improves Crohn's disease in a patient with myelodysplastic syndrome that developed from aplastic anemia: A case report. <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.4	0
3	Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1323-1330.	0.6	10
4	Amplified <i>EPOR</i> / <i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 410-427.	2.6	7
5	Natural history of inferior mesenteric arteriovenous malformation that led to ischemic colitis: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 396-402.	0.3	1
6	Progranulin depletion inhibits proliferation via the transforming growth factor beta/SMAD family member 2 signaling axis in Kasumi-1 cells. <i>Heliyon</i> , 2021, 7, e05849.	1.4	5
7	Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey. <i>Internal Medicine</i> , 2021, 60, 699-707.	0.3	6
8	Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 194, 325-335.	1.2	9
9	Viability of diffuse large B-cell lymphoma cells is regulated by kynurenine 3-monooxygenase activity. <i>Oncology Letters</i> , 2021, 22, 790.	0.8	4
10	Clinical significance of oxidative stress for untreated patients with diffuse large B-cell lymphoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 4.	0.4	1
11	<i>EPOR</i> / <i>JAK</i> / <i>STAT</i> Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. <i>Blood</i> , 2021, 138, 610-610.	0.6	2
12	Hypocellular Philadelphia chromosome-positive mixed phenotype acute leukemia successfully treated with dasatinib: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 16, 33.	0.4	0
13	Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction. <i>International Journal of Hematology</i> , 2020, 111, 585-590.	0.7	2
14	Indoleamine 2,3-Dioxygenase Activity Is Increased in Myelodysplastic Syndrome Patients. <i>Hemato</i> , 2020, 1, 77-85.	0.2	0
15	Low Levels of Serum Tryptophan Underlie Skeletal Muscle Atrophy. <i>Nutrients</i> , 2020, 12, 978.	1.7	25
16	Evaluation of the effectiveness of caspofungin against febrile neutropenia and the factors related to the alteration in its plasma concentration. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 801-805.	0.8	3
17	Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 723-730.	0.7	7
18	Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2019, 98, 351-359.	0.8	23

#	ARTICLE	IF	CITATIONS
19	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 675-675.	0.6	17
20	Trends in Transmitted Drug Resistance and Prevalence of Non-B Subtype in Newly Diagnosed Individuals with HIV-1 in the Tokai Area. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2019, 93, 298-305.	0.0	0
21	Prevalence of HIV-1 Integrase Polymorphisms and Drug Resistance Mutations in Newly Diagnosed Individuals with HIV-1 in the Tokai Area. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2019, 93, 312-318.	0.0	1
22	Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. <i>International Journal of Clinical Oncology</i> , 2018, 23, 980-988.	1.0	15
23	THP versus CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial. <i>Hematological Oncology</i> , 2018, 36, 638-644.	0.8	23
24	CHOP or THP versus CHOP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. <i>Hematological Oncology</i> , 2017, 35, 163-171.	0.8	7
25	Serum concentrations of L-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified. <i>Hematological Oncology</i> , 2017, 35, 637-644.	0.8	6
26	A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother. <i>Hematological Oncology</i> , 2017, 35, 288-295.	0.8	8
27	Association between increased serum GP88 (progranulin) concentrations and prognosis in patients with malignant lymphomas. <i>Clinica Chimica Acta</i> , 2017, 473, 139-146.	0.5	25
28	Control of Constipation in Patients Receiving CHOP or CHOP-Like Chemotherapy Regimens for Non-Hodgkin's Lymphoma. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 698-702.	0.6	8
29	The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis. <i>PLoS ONE</i> , 2016, 11, e0146279.	1.1	20
30	Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. <i>Leukemia Research</i> , 2016, 51, 11-18.	0.4	7
31	Multiple myeloma with Russell bodies and needle-shaped crystalline inclusions. <i>International Journal of Hematology</i> , 2016, 103, 483-485.	0.7	1
32	Prognostic value of the combination of serum L-kynurenine level and indoleamine 2,3-dioxygenase mRNA expression in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2208-2211.	0.6	9
33	High serum concentration of L-kynurenine predicts unfavorable outcomes in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 92-98.	0.6	33
34	Efficacy of rituximab maintenance therapy for aggressive B-cell lymphoma depends on use of rituximab in induction therapy: a meta-analysis of randomized controlled trials. <i>Haematologica</i> , 2015, 100, e519-e520.	1.7	8
35	Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. <i>International Journal of Hematology</i> , 2015, 102, 327-334.	0.7	19
36	Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2015, 94, 2043-2053.	0.8	72

#	ARTICLE	IF	CITATIONS
37	Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. <i>Leukemia and Lymphoma</i> , 2015, 56, 1398-1405.	0.6	35
38	Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen. <i>Journal of Clinical and Experimental Hematopathology</i> : JCEH, 2014, 54, 117-127.	0.3	4
39	Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1691-1693.	0.6	6
40	Mantle cell lymphoma with a unique pattern of CD5 expression: a case report with review of the literatures. <i>Medical Molecular Morphology</i> , 2014, 47, 169-175.	0.4	5
41	Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats. <i>Oncology Letters</i> , 2014, 8, 223-229.	0.8	13
42	Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study. <i>Blood</i> , 2014, 124, 4537-4537.	0.6	3
43	Clinical significance of jejunoileal involvement of non-Hodgkin's lymphoma detected by double-balloon enteroscopy. <i>International Journal of Hematology</i> , 2013, 97, 369-381.	0.7	2
44	Enhanced Development of Azoxymethane-Induced Colonic Preneoplastic Lesions in Hypertensive Rats. <i>International Journal of Molecular Sciences</i> , 2013, 14, 14700-14711.	1.8	11
45	Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the CHOP regimen. <i>European Journal of Haematology</i> , 2013, 91, 322-331.	1.1	15
46	Effects of Indoleamine 2,3-Dioxygenase Deficiency on High-Fat Diet-Induced Hepatic Inflammation. <i>PLoS ONE</i> , 2013, 8, e73404.	1.1	53
47	A phase II study of rituximab combined with pirarubicin, cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 247-253.	0.6	2
48	Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1494-1500.	0.6	22
49	Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1143-1145.	0.6	22
50	(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. <i>Oncology Letters</i> , 2012, 4, 546-550.	0.8	46
51	Cerebriform variant type of T cell prolymphocytic leukemia with complex karyotype including an additional segment at 1p36.1. <i>International Journal of Hematology</i> , 2012, 96, 674-678.	0.7	1
52	First report of drug-induced esophagitis by deferasirox. <i>International Journal of Hematology</i> , 2012, 95, 689-691.	0.7	3
53	Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. <i>Annals of Hematology</i> , 2012, 91, 705-714.	0.8	58
54	Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 5-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. <i>Cancer Science</i> , 2012, 103, 951-958.	1.7	33

#	ARTICLE	IF	CITATIONS
55	Phase II study of the tetrahydropyranyl adriamycin cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 629-634.	0.6	25
56	Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. <i>European Journal of Haematology</i> , 2011, 87, 217-227.	1.1	27
57	Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 779-787.	1.2	12
58	Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Annals of Hematology</i> , 2011, 90, 409-416.	0.8	77
59	Coexistence of inversion 16 and the Philadelphia chromosome comprising P190 BCR/ABL in chronic myeloid leukemia blast crisis. <i>International Journal of Hematology</i> , 2011, 93, 806-810.	0.7	17
60	Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. <i>Cancer Prevention Research</i> , 2011, 4, 2092-2100.	0.7	54
61	Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 65-70.	1.2	22
62	Serum concentration of kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>European Journal of Haematology</i> , 2010, 84, 304-309.	1.1	70
63	Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. <i>Cancer Science</i> , 2010, 101, 1701-1707.	1.7	61
64	Cell Cycle-Dependent Priming Action of Granulocyte Colony-Stimulating Factor (G-CSF) Enhances in vitro Apoptosis Induction by Cytarabine and Etoposide in Leukemia Cell Lines. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2010, 50, 99-105.	0.3	15
65	Supplementation with Branched-chain Amino Acids Inhibits Azoxymethane-induced Colonic Preneoplastic Lesions in Male C57BL/KsJ-db/db Mice. <i>Clinical Cancer Research</i> , 2009, 15, 3068-3075.	3.2	60
66	Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 53-59.	1.2	31
67	Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1421-1428.	1.2	15
68	Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. <i>Hematological Oncology</i> , 2008, 26, 33-38.	0.8	7
69	Retinoid X receptor is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. <i>Leukemia Research</i> , 2008, 32, 884-892.	0.4	13
70	(-)-Epigallocatechin Gallate Suppresses Azoxymethane-Induced Colonic Premalignant Lesions in Male C57BL/KsJ-db/db Mice. <i>Cancer Prevention Research</i> , 2008, 1, 298-304.	0.7	94
71	EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. <i>Molecular Medicine Reports</i> , 2008, 1, 355-61.	1.1	43
72	Synergistic effects of RXR and PPAR ligands to inhibit growth in human colon cancer cells phosphorylated RXR is a critical target for colon cancer management. <i>Gut</i> , 2007, 56, 1557-1563.	6.1	89

#	ARTICLE	IF	CITATIONS
73	A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2007, 25, 107-114.	0.8	43
74	Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. <i>Cancer Science</i> , 2007, 98, 431-437.	1.7	54
75	Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 547-553.	1.2	13
76	Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2006, 77, 217-225.	1.1	34
77	Low-Dose Granulocyte Colony-Stimulating Factor Overcomes Neutropenia in the Treatment of Non-Hodgkin's Lymphoma with Higher Cost-Effectiveness. <i>International Journal of Hematology</i> , 2005, 82, 430-436.	0.7	3
78	Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. <i>Pathology International</i> , 2005, 55, 324-330.	0.6	32
79	Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 73-79.	1.2	56
80	Prevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma. <i>Intervirolgy</i> , 2005, 48, 39-45.	1.2	74
81	Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 107-113.	1.2	42
82	A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. <i>European Journal of Haematology</i> , 2002, 68, 354-361.	1.1	29
83	Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2000, 64, 257-261.	2.0	41
84	Prognostic Impact of Six Versus Eight Cycles of Standard Regimen in Patients With Diffuse Large B-Cell Lymphoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
85	Phlegmonous gastritis as the initial presentation of acute myeloid leukaemia. <i>EJHaem</i> , 0, , .	0.4	0